CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML
Authors
Hills, RobertBurnett, Alan
Lucas, Claire
Scott, Laura
Carmell, Natasha
Holcroft, Alison
Clark, Richard
Affiliation
University of Liverpool, Royal Liverpool University hospital, University of CardiffPublication Date
2018-04-27
Metadata
Show full item recordAbstract
Key Points PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.Citation
Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K. & Clark, R. E. (2018). CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood advances, 2(9), 964-8.Publisher
American Society for HematologyJournal
Blood AdvancesAdditional Links
http://www.bloodadvances.org/content/2/9/964/tab-article-infoType
ArticleLanguage
enEISSN
2473-95292473-9537
ae974a485f413a2113503eed53cd6c53
10.1182/bloodadvances.2017013615
Scopus Count
Collections
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/